Evidence map›Paper›PMID 40217414›Full record

ArticleActa epileptologica2025

Fasciola cinereum: a novel choke point for epilepsy treatment.

Lilong Yu, Dongxiao Jiang, Yi Wang, Zhong Chen, Lin Yang

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta epileptologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lilong YuKey Laboratory of Neuropharmacology and Translational Medicine of Zhejiang Province, The First Affiliated Hospital, School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, China.
Dongxiao JiangKey Laboratory of Neuropharmacology and Translational Medicine of Zhejiang Province, The First Affiliated Hospital, School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, China.
Yi WangKey Laboratory of Neuropharmacology and Translational Medicine of Zhejiang Province, The First Affiliated Hospital, School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, China.
Zhong ChenKey Laboratory of Neuropharmacology and Translational Medicine of Zhejiang Province, The First Affiliated Hospital, School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, China.
Lin YangKey Laboratory of Neuropharmacology and Translational Medicine of Zhejiang Province, The First Affiliated Hospital, School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, China. linyang52@163.com.

Funding

China Postdoctoral Science Foundation 2023M743145National Natural Science Foundation of China 82373859
6 · The paper itself

Abstract

Ablation of seizure foci represents a crucial therapeutic approach for epilepsy. Traditionally, the seizure foci are predominantly located in the anterior hippocampus and amygdala. However, recent research by Ivan Soltesz and his colleagues described the posterior hippocampal fasciola cinereum (FC) as a region activated during seizures. Their findings demonstrate that inhibition and ablation of FC reduce seizures frequency. Therefore, FC emerges as a critical seizure node within the posterior hippocampus, playing an important role in epilepsy treatment.

Indexed as

Epilepsy treatmentFasciola cinereumSeizure node

Identifiers

PMID40217414
PMCPMC11960240

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.